These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 16156840)

  • 1. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.
    Vieweg WV; Schneider RK; Wood MA
    Acta Psychiatr Scand; 2005 Oct; 112(4):318-22; author reply 322. PubMed ID: 16156840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulpiride induced torsade de pointes.
    Huang BH; Hsia CP; Chen CY
    Int J Cardiol; 2007 Jun; 118(3):e100-2. PubMed ID: 17408770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin and torsade de pointes.
    Dale KM; Lertsburapa K; Kluger J; White CM
    Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Torsade de pointes and low-dose oral haloperidol.
    Jackson T; Ditmanson L; Phibbs B
    Arch Intern Med; 1997 Sep; 157(17):2013-5. PubMed ID: 9308514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.
    Zeltser D; Justo D; Halkin A; Prokhorov V; Heller K; Viskin S
    Medicine (Baltimore); 2003 Jul; 82(4):282-90. PubMed ID: 12861106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
    Tisdale JE; Kovacs R; Mi D; McCabe GP; Cariera BL; Sharma N; Rosman H
    Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
    Glassman AH
    J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long QTc interval and torsade de pointes caused by fluconazole.
    Pham CP; de Feiter PW; van der Kuy PH; van Mook WN
    Ann Pharmacother; 2006; 40(7-8):1456-61. PubMed ID: 16849620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Iatrogenic torsade de pointes induced by thioridazine].
    Paoloni P; Ciliberti D; Blasi N; Capone P
    Minerva Cardioangiol; 1992 Jun; 40(6):245-9. PubMed ID: 1407620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.
    Calderone V; Testai L; Martinotti E; Del Tacca M; Breschi MC
    J Pharm Pharmacol; 2005 Feb; 57(2):151-61. PubMed ID: 15720777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.
    Glassman AH; Bigger JT
    Am J Psychiatry; 2001 Nov; 158(11):1774-82. PubMed ID: 11691681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
    Gury C; Canceil O; Iaria P
    Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT interval prolongation and torsade de pointes.
    Patanè S; Marte F; Di Bella G
    Int J Cardiol; 2009 Jan; 131(2):e51-3. PubMed ID: 17689729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Torsade de Pointes with T wave alternans in a patient receiving moderate dose of chlorpromazine: report of a case].
    Ochiai H; Kashiwagi M; Usui T; Oyama Y; Tokita Y; Ishikawa T
    Kokyu To Junkan; 1990 Aug; 38(8):819-22. PubMed ID: 2218093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P; Hreiche R; Turgeon J
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torsade de pointes following intravenous haloperidol administration in a patient with complete heart block.
    Ginwalla M; Biblo LA; Paydak H
    WMJ; 2009 Feb; 108(1):48-50. PubMed ID: 19326637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haloperidol-induced torsade de pointes.
    O'Brien JM; Rockwood RP; Suh KI
    Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QT interval prolongation and torsade de pointes associated with indapamide.
    Letsas KP; Alexanian IP; Pappas LK; Kounas SP; Efremidis M; Sideris A; Kardaras F
    Int J Cardiol; 2006 Oct; 112(3):373-4. PubMed ID: 16260053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.